Request FREE sample PDF
Pharmacy benefit management market
Ovarian Cancer Market Report Overview
The global ovarian cancer market size was USD 1970.9 million in 2022 and is projected to touch USD 4460.43 million by 2031, exhibiting a CAGR of 9.5% during the forecast period.
Ovarian cancer is the most common type of cancer that begins in the ovaries. It is usually found in women. Stromal tumor, epithelial tumor, and germ cell tumors are the type of ovarian cancer.
Increased prevalence of ovarian cancer among population and progress & innovations in the pharmaceutical sector for the manufacturing of the cancer drugs. Growing health-conscious consumers and rapid product approval of various drugs to treat cancer is predicted to drive market growth. Increased number of elderly population and growing need for oral drugs are anticipated to accelerate market growth in the forthcoming years. Growing healthcare spending and easy availability of medicines are projected to drive market progress. Further, improvement in the structure of hospital pharmacy and the availability of cutting-edge therapies. These are the key factors is estimated to drive market progress in the upcoming years. On the contrary, lack of skilled professional and high cost of the treatment method is anticipated to hamper market growth in the upcoming years.
COVID-19 Impact: Difficulties to Administer to Halt Market Progress
The global COVID-19 pandemic has been unprecedented and staggering, with ovarian cancer experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden spike in CAGR is attributable to demand returning to pre-pandemic levels once the pandemic is over.
The market through in the disruption to clinical trials and the outbreak of the COVID-19 pandemic affected most crucial areas of the market growth. The market witness difficulties to administer chemotherapy. Also, several treatments were performing outside of clinic due to clinics were full with COVID-19 patients.
LATEST TRENDS
"Increasing number of Elderly Population to Fuel Market Growth "
Increasing number of elderly population and growing patient population is expected to drive market growth. According to the WHO, elderly population is anticipated reach around 2 billion by 2050 from 617 million in 2015. These elderly population is possibly like to get infected with ovarian cancer is predicted to drive market progress in the upcoming years. Growing healthcare spending and easy availability of medicines are projected to drive market progress. Further, improvement in the structure of hospital pharmacy and the availability of cutting-edge therapies. These are the key factors id estimated to drive ovarian cancer market progress in the upcoming years.
Ovarian Cancer Market Segmentation
- By Type
Based on type, the market is divided into surgery, chemotherapy, radiation, biological therapy, and ovarian cancer.
Surgery is expected to be the top part of type segmentation
- By Application
Based on the application, the market is divided into hospitals, clinics, and others.
Hospitals are expected to be the top part of application segmentation.
DRIVING FACTORS
"Increased Number of Ovarian Cancer among Growing Population to Surge Market Growth "
Ovarian cancer is the third most common cancer worldwide. Ovarian cancer is the most common type of cancer that begins in the ovaries. It is usually found in women. Stromal tumor, epithelial tumor, and germ cell tumors are the type of ovarian cancer. Increased women population and high demand to treat the cancer. According to the American Cancer Society, approx. 19,880 new cases of the cancer will be diagnosed and in 2022 around 12,810 women died of the cancer. Such, growing number of cancer cases worldwide is expected to fuel market progress in the forthcoming years.
"Growing Healthcare Awareness and Increased Need for Oral Drugs to Improve Market Growth "
Growing healthcare awareness among population is rising the adoption of the drugs. Innovative launches in medication for the treatment of cancer and ongoing R&D activities is predicted to creates more opportunity in the market. Increased prevalence of ovarian cancer among population and progress & innovations in the pharmaceutical sector for the manufacturing of the cancer drugs. Growing health-conscious consumers and rapid product approval of various drugs to treat cancer is predicted to drive market growth. Increased number of elderly population and growing need for oral drugs are anticipated to accelerate market growth in the forthcoming years. Growing healthcare spending and easy availability of medicines are projected to drive market progress. Further, improvement in the structure of hospital pharmacy and the availability of cutting-edge therapies is predicted to improve market progress in the forthcoming years.
RESTRAINING FACTORS
Lack of skilled professional and high cost of the treatment method is anticipated to hamper market growth in the upcoming years.
Ovarian Cancer Market Regional Insights
"Presence of Main Generic Pharmaceutical Companies in Asia Pacific to Drive Market Share "
Asia Pacific is anticipated to account for the highest ovarian cancer market share owing to the presence of main generic pharmaceutical companies. Rise in special communities and government initiatives is projected to drive market growth. Increased number of elderly population and growing need for oral drugs are anticipated to accelerate market growth in the forthcoming years. Growing healthcare spending and easy availability of medicines are projected to drive market progress. Further, improvement in the structure of hospital pharmacy and the availability of cutting-edge therapies. These are the key factors is estimated to drive market progress in the upcoming years.
North America is expected to dominate market growth owing to increase in women population, large availability of treatment options. According to the American Cancer Society, approx. 19,880 new cases of the cancer will be diagnosed and in 2022 around 12,810 women died of the cancer. Such, growing number of cancer cases worldwide is expected to fuel market progress in the forthcoming years.
KEY INDUSTRY PLAYERS
"Leading Players Adopt New Strategies to Stay Competitive"
The report covers information about the list of market players and their latest development in the industry. The information includes mergers, partnerships, acquisitions, technological developments, and production lines. Other aspects examined for this market include complete research on companies producing and introducing the latest products, regions they conduct their operations in, automation, technology adoption, generating the most revenue, and making a difference with their products.
LIST OF TOP OVARIAN CANCER COMPANIES
- Bristol Myers Squibb (U.S.)
- Eli Lilly (U.S.)
- GlaxoSmithKline (U.K.)
- Janssen Pharmaceuticals (U.S.)
- Novogen (India)
- Genentech (U.S.)
- Aetera Zenteris (U.S.)
- Boehringer Ingelheim (Germany)
- Roche (Switzerland)
REPORT COVERAGE
This research profiles a report with general studies that explain the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by examining the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, and others. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 1970.9 Million in 2022 |
Market Size Value By |
US$ 4460.43 Million by 2031 |
Growth Rate |
CAGR of 9.5% from 2022 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the ovarian cancer market expected to touch by 2031?
The global ovarian cancer market size is expected to reach USD 4460.43 million by 2031.
-
What CAGR is the ovarian cancer market expected to exhibit by 2031?
The ovarian cancer market is expected to exhibit a CAGR of 9.5% by 2031.
-
Which are the driving factors of the ovarian cancer market?
Drivers of this ovarian cancer market are increased number of ovarian cancer among growing population and growing healthcare awareness and increased need for oral drugs.
-
Which are the top companies operating in the ovarian cancer market?
Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novogen, Genentech, Aetera Zenteris, Boehringer Ingelheim, and Roche are the top companies operating in the ovarian cancer market.